Formycon Adjusts 2026 Financial Outlook Amid Market Changes

Formycon AG has reaffirmed its 2026 guidance for revenue, EBITDA, and working capital while revising adjusted EBITDA and reassessing two key products, FYB201 and FYB202. Revenue projections remain between EUR 60 to 70 million, and EBITDA is expected at EUR 0 to 10 million, both at the lower range. Adjusted EBITDA is revised to EUR -15 million to EUR -5 million, influenced by competitive pressures affecting their commercialization partners.

The company expects reduced revenue due to increased competition in the ranibizumab and ustekinumab markets. As a result, non-cash impairments of EUR 82 million for FYB202 and EUR 39 million for FYB201 have been charged. However, future biosimilar developments, like FYB206 and FYB208, remain unaffected. The repercussions on financial metrics do not involve cash flow, leaving partner agreements intact.